Journal ArticleDOI
Management of hand-foot syndrome induced by capecitabine.
TLDR
Treatment interruption or dose reduction remain the only methods shown to effectively manage HFS, but supportive measures to reduce pain and discomfort and prevent secondary infection are very important.Abstract:
Introduction. Capecitabine (Xeloda®) is a systemic prodrug of 5-fluorouracil (5-FU), which is administered in an oral formulation. Hand-foot syndrome (HFS) has proven to be a chronic dose-limiting toxicity of capecitabine, leading to significant morbidity in patients receiving this agent. The purpose of this review is to define the pathophysiology, risk factors, incidence and management of capecitabine-induced HFS.Methods. Literature for this review article was collected from the following databases: PubMed, CINAHL, and the proceedings of the American Society of Clinical Oncology (ASCO) confined to the years 1995-2006. The following key terms were used in the search: hand-foot syndrome, palmar-plantar erythrodysesthesia, capecitabine, Xeloda®, colorectal cancer, and metastatic breast cancer.Results. HFS associated with capecitabine is a serious dose-limiting toxicity. Incidence of grade 3/4 toxicity is of extreme significance, and introduces the need for dose reductions and/or interruptions in capecitabin...read more
Citations
More filters
Journal ArticleDOI
Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib After Cardiac Surgery
Journal ArticleDOI
Effects of 5-Fluorouracil on Morphology, Cell Cycle, Proliferation, Apoptosis, Autophagy and ROS Production in Endothelial Cells and Cardiomyocytes
Chiara Focaccetti,Antonino Bruno,Elena Magnani,Desirée Bartolini,Elisa Principi,Katiuscia Dallaglio,Eraldo O. Bucci,Giovanna Finzi,Fausto Sessa,Douglas M. Noonan,Adriana Albini +10 more
TL;DR: 5-FU can affect, both at the cellular and molecular levels, two key cell types of the cardiovascular system, potentially explaining some manifestations of 5-FU-induced cardiovascular toxicity.
Journal ArticleDOI
Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): Focus on Sorafenib and Sunitinib
TL;DR: A review of the epidemiology, clinical features, histopathology, pathogenesis models, prognostic implications, and management of hand-foot syndrome, with particular attention to HFS induced by sorafenib and sunitinib.
Journal ArticleDOI
A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer
Miguel Martin,Jacques Bonneterre,Charles E. Geyer,Yoshinori Ito,Jungsil Ro,István Láng,Sung-Bae Kim,C. Germa,Jennifer Vermette,Kenneth Wang,Kongming Wang,Ahmad Awada +11 more
TL;DR: The study confirmed relevant single-agent clinical activity and acceptable overall tolerability of neratinib in patients with recurrent HER2+ advanced breast cancer and no significant skin toxicity was found.
Journal ArticleDOI
Impact of Dermatologic Adverse Events on Quality of Life in 283 Cancer Patients: A Questionnaire Study in a Dermatology Referral Clinic
Alyx C. Rosen,Emily C. Case,Stephen W. Dusza,Yevgeniy Balagula,Jennifer Gordon,Dennis P. West,Mario E. Lacouture +6 more
TL;DR: Dermatologic AEs are associated with a diminished QoL in patients on conventional versus targeted anti-cancer therapies using a dermatology-specific questionnaire, and targeted therapies areassociated with a significantly increased number of AEs and worse total and emotion Skindex-16 scores in comparison with non-targeted therapies.
References
More filters
Journal ArticleDOI
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial
Robert S. Bresalier,Robert S. Sandler,Hui Quan,James A. Bolognese,Bettina Oxenius,Kevin J. Horgan,Christopher Lines,Robert H. Riddell,Dion Morton,Angel Lanas,Marvin A. Konstam,John A. Baron +11 more
TL;DR: Among patients with a history of colorectal adenomas, the use of rofecoxib was associated with an increased cardiovascular risk, and cardiovascular mortality was similar in the two groups.
Journal ArticleDOI
Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Scott D. Solomon,John J.V. McMurray,Marc A. Pfeffer,Janet Wittes,Robert A. Fowler,Peter V. Finn,William F. Anderson,Ann G. Zauber,Ernest T. Hawk,Monica M. Bertagnolli +9 more
TL;DR: Celecoxib use was associated with a dose-related increase in the composite end point of death from cardiovascular causes, myocardial infarction, stroke, or heart failure, providing further evidence that the use of COX-2 inhibitors may increase the risk of serious cardiovascular events.
Journal ArticleDOI
Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer
Kathy D. Miller,Linnea I. Chap,Frankie A. Holmes,Melody A. Cobleigh,P. Kelly Marcom,Louis Fehrenbacher,Maura N. Dickler,Beth Overmoyer,James D. Reimann,Amy P. Sing,Virginia K. Langmuir,Hope S. Rugo +11 more
TL;DR: Although the addition of bevacizumab to capecitabine produced a significant increase in response rates, this did not translate into improved PFS or overall survival.
Journal ArticleDOI
Capecitabine as Adjuvant Treatment for Stage III Colon Cancer
Chris Twelves,A. Wong,M. Nowacki,Markus Abt,Howard A. Burris,Alfredo Carrato,Jim Cassidy,Andrés Cervantes,Jan Fagerberg,Vassilis Georgoulias,Fares Husseini,Duncan I. Jodrell,P. Koralewski,Hendrik Kröning,Jean A. Maroun,Norbert Marschner,Joseph McKendrick,M. Pawlicki,Riccardo Rosso,Johannes Schüller,Jean-François Seitz,Borut Stabuc,Jerzy Tujakowski,Guy van Hazel,Jerzy Zaluski,Werner Scheithauer +25 more
TL;DR: Oral capecitabine is an effective alternative to intravenous fluorouracil plus leucovorin in the adjuvant treatment of colon cancer.
Journal ArticleDOI
Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study
Paulo M. Hoff,Rafat Ansari,Gerald Batist,John Cox,Walter Kocha,Mario Kuperminc,Jean A. Maroun,David Walde,Charles Weaver,Evelyn Harrison,Hans U. Burger,Bruno Osterwalder,A. Wong,Ralf Wong +13 more
TL;DR: Oral capecitabine was more active than 5-FU/LV in the induction of objective tumor responses and demonstrated clinically meaningful benefits over bolus 5-fu/ LV in terms of tolerability.
Related Papers (5)
Management of hand-foot syndrome in patients treated with capecitabine (Xeloda®)
Yvonne Lassere,Paulo M. Hoff +1 more
Capecitabine as Adjuvant Treatment for Stage III Colon Cancer
Chris Twelves,A. Wong,M. Nowacki,Markus Abt,Howard A. Burris,Alfredo Carrato,Jim Cassidy,Andrés Cervantes,Jan Fagerberg,Vassilis Georgoulias,Fares Husseini,Duncan I. Jodrell,P. Koralewski,Hendrik Kröning,Jean A. Maroun,Norbert Marschner,Joseph McKendrick,M. Pawlicki,Riccardo Rosso,Johannes Schüller,Jean-François Seitz,Borut Stabuc,Jerzy Tujakowski,Guy van Hazel,Jerzy Zaluski,Werner Scheithauer +25 more